

Liste der bewilligten Forschungsprojekte 2024 *Liste des projets de recherche acceptés en 2024*

Im [Forschungsportal](#) finden Sie Informationen zu allen Projekten, die die Stiftung Krebsforschung Schweiz und ihre Partnerorganisation Krebsliga Schweiz seit dem Jahr 2005 gefördert haben.

Dans le [portail de recherche](#), vous trouverez les informations sur tous les projets soutenus par la fondation Recherche suisse contre le cancer et son organisation partenaire, la Ligue suisse contre le cancer, depuis 2005.

Basic research

Arnold Isabelle | Exploring eosinophil function in progressive colorectal cancer stages and metastasis in the era of transcriptomics

Institute of Experimental Immunology, Universität Zürich (UZH), Zurich

CHF 369 644 | 36 months | [KFS-6248-08-2024](#)

Basler Konrad | Investigating the similarities and differences between left- and right-sided colon cancer: a metastasis focus

Institut für Molekulare Biologie, Universität Zürich (UZH), Zürich

CHF 207 500 | 18 months | [KFS-6031-02-2024](#)

Becher Burkhard | Targeting IL-23R on tumour-infiltrating Tregs for cancer immunotherapy

Institute of Experimental Immunology, Universität Zürich (UZH), Zürich

CHF 351 578 | 36 months | [KFS-6022-02-2024](#)

Beerenwinkel Niko | Profiling tumour evolution in ovarian cancer for precision oncology

Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule (ETH), Basel

CHF 373 051 | 36 months | [KFS-6058-02-2024](#)

Cejka Petr | Towards mechanistic understanding of secondary DNA structure processing underlying synthetic lethality in cancer therapy

USI, Istituto di Ricerca in Biomedicina (IRB), Bellinzona

CHF 369 060 | 36 months | [KFS-6136-08-2024](#)

Coukos George | Laboratory evolution of cell states for next generation T cell cancer immunotherapy

Department of Oncology, Centre hospitalier universitaire vaudois (CHUV), Lausanne

CHF 358 143 | 48 months | [KFS-6060-02-2024](#)

De Palma Michele | Rewiring lung cancer immunity with engineered dendritic cell progenitors

Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne

CHF 366 980 | 48 months | [KFS-6045-02-2024](#)

Fernandez Gonzalez Santiago | Influence of the lymphatic versus hematogenous dissemination of B cell lymphoma in the immune response

Infection and Immunity, Istituto di Ricerca in Biomedicina (IRB), Bellinzona

CHF 346 738 | 48 months | [KFS-6092-02-2024](#)

Gönczy Pierre | Uncovering centriole number control mechanisms in health and cancer

SV ISREC UPGON, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne 15

CHF 373 980 | 36 months | [KFS-6018-02-2024](#)

Hess Christoph | Defining the metabolic and non-metabolic roles of QPRT in EBV-driven B cell lymphoma

Departement Biomedizin (DBM), Universität Basel, Basel

CHF 374 535 | 36 months | [KFS-6254-08-2024](#)

Janscak Pavel | Revisiting the molecular mechanisms underlying DNA replication stress induced by the chemotherapeutic agents cisplatin and mitomycin C

Institut für Molekulare Krebsforschung (Doppelinstitut MeF/MNF) (IMCR), Universität Zürich (UZH), Zürich

CHF 249 852 | 24 months | [KFS-6145-08-2024](#)

Jourdain Alexis | Blocking nucleoside catabolism to starve tumours

Immunobiology (formerly Biochemistry), Université de Lausanne (UNIL), Epalinges

CHF 375000 | 48 months | [KFS-6029-02-2024](#)

Marti Thomas | Repurposing of the anti-epileptic drug stiripentol for cancer therapy

Clinic of Thoracic Surgery, Inselspital Bern, Bern

CHF 371 250 | 36 months | [KFS-6228-08-2024](#)

Nombela Arrieta Cesar | Inflammation-driven remodeling of the bone marrow microenvironment in the pathogenesis of acute myeloid leukemia

Medical Oncology and Hematology, Universität Zürich (UZH), Zürich

CHF 374 656 | 48 months | [KFS-6235-08-2024](#)

Pruschy Martin | Impact of draining lymph node irradiation during radioimmunotherapy on tumour dissemination

Departement für Radio-Onkologie, Universitätsspital Zürich (USZ), Zürich

CHF 249 240 | 24 months | [KFS-6223-08-2024](#)

Riek Roland | A new strategy to treat MAPK inhibitor resistant melanomas using the amyloid fold

Departement Chemie und Angewandte Biowissenschaften (D-CHAB), Eidgenössische Technische Hochschule (ETH), Zürich

CHF 374 640 | 48 months | [KFS-6068-02-2024](#)

Stucki Manuel | Targeting mitotic DNA damage tolerance pathways as a strategy to treat BRCA1/2-deficient cancers

Department of Gynecology, Universitätsspital Zürich (USZ), Schlieren

CHF 299 439 | 36 months | [KFS-6185-08-2024](#)

Tamburini Jerome | Targeting iron metabolism to eliminate quiescent leukemic stem cells in acute myeloid leukaemia

Medical specialities, Université de Genève (UNIGE), Genève

CHF 369 619 | 36 months | [KFS-6032-02-2024](#)

Theurillat Jean-Philippe | Understanding and co-targeting FOXA1 & FOXA2 in prostate cancer progression

Institute of Oncology Research, Institute of Oncology Research (IOR), Bellinzona

CHF 368 532 | 36 months | [KFS-6178-08-2024](#)

Weller Michael | Vortioxetine against glioblastoma: drug repurposing meets cancer neuroscience

Department of Neurology and Laboratory of Molecular Neurooncology, Universitätsspital Zürich (USZ), Zurich

CHF 341 833 | 36 months | [KFS-6084-02-2024](#)

Zavolan Mihaela | Discovery and functional characterization of HCC-associated small peptides

Biozentrum, Universität Basel, Basel

CHF 371 379 | 36 months | [KFS-6181-08-2024](#)

Clinical Research – laboratory-oriented

Bertholet Jenny | Simultaneous optimization of radiation therapy in space and time: a new horizon for Temporally Feathered Radiation Therapy (TFRT)

Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital Bern, Bern

CHF 249 826 | 48 months | [KFS-6163-08-2024](#)

Latorre Daniela | The immune cells in checkpoint inhibitor-associated neuromuscular inflammation - dissecting potential therapeutic targets

D-Biol, Eidgenössische Technische Hochschule (ETH), Zurich

CHF 364 265 | 36 months | [KFS-6205-08-2024](#)

Moeckli Raphaël | FLIRT: FLASH irradiation treatment planning to facilitate and optimize glioblastoma treatments with very-high energy electron FLASH radiation therapy

Institut de Radiophysique, Centre hospitalier universitaire vaudois (CHUV), Lausanne

CHF 251 143 | 48 months | [KFS-6020-02-2024](#)

Perentes Jean Yannis | Understanding how the immunogenic cell death caused by hyperthermic intrathoracic cisplatin chemotherapy improves the control of malignant pleural disease alone or in combination with immunotherapy

Service de chirurgie thoracique, Centre hospitalier universitaire vaudois (CHUV), Lausanne

CHF 322 614 | 36 months | [KFS-6215-08-2024](#)

Vassella Erik | Overcoming resistance to temozolomide and immunotherapy by targeting the nonsense-mediated mRNA decay pathway in glioblastoma tumours

Institute of Tissue Medicine and Pathology, Universität Bern (UniBE), Bern

CHF 349 842 | 48 months | [KFS-6061-02-2024](#)

Wirsching Hans-Georg | Radiation-associated meningioma molecular profiling to inform targeted therapies (RAMPIT)

Neurology, UniversitätsSpital Zürich (USZ), Zürich

CHF 371 188 | 48 months | [KFS-6103-02-2024](#)

Zippelius Alfred | Unravelling the relevance of intratumoral NK cell subtypes in lung cancer using multimodal single cell and spatial analysis

Medical Oncology, Laboratory Cancer Immunology, Department Biomedicine, Universitätsspital Basel (USB), Basel

CHF 304 265 | 24 months | [KFS-6233-08-2024](#)

Clinical Research – patient-oriented

Bösch Maximilian | Fibre-Boost: A multicentre, 2:1 randomized, controlled trial to study the effects of a high-fibre dietary intervention on ctDNA clearance and the microbial and immunological landscape in immune checkpoint blockade-treated advanced non-small cell lung cancer

Lung Center, Kantonsspital St. Gallen (KSSG), St.Gallen

CHF 374 950 | 36 months | [KFS-6039-02-2024](#)

Gotta Verena | Prospective pharmacologic characterization of a novel cytomegalovirus-infection prophylaxis (Letermovir) in paediatric hematopoietic cell transplantation patients using endogenous Coproporphyrin (LetPeCo)

Pädiatrische Klinische Pharmazie / Pediatric Pharmacology and Pharmacometrics, Universitäts-Kinderspital beider Basel (UKBB), Basel

CHF 167 580 | 42 months | [KFS-6041-02-2024](#)

Heinzelmann-Schwarz Viola | Continuation of MATAO-Trial “Maintenance therapy with aromatase inhibitor in epithelial ovarian cancer: a phase III randomized double-blind placebo-controlled trial”

Gynecological Oncology, Universitätsspital Basel (USB), Basel

CHF 357 846 | 36 months | [KFS-6066-02-2024](#)

Petignat Patrick | Validation of AI-assisted digital telecytology for the triage of HPV-positive women in a same-day ‘Test-triage-treat’ strategy in Cameroon

Unité d'oncogynécologie chirurgicale, Université de Genève (UNIGE), Genève

CHF 375 000 | 36 months | [KFS-6044-02-2024](#)

Toso Christian | Assessing the impact of surgery on the immunity against hepatocellular carcinoma and on the use of immune check point inhibitors

Université de Genève (UNIGE)

CHF 370 517 | 36 months | [KFS-6186-08-2024](#)

Weber Walter Paul | Tailored axillary surgery de-escalation in patients with clinically node-positive breast cancer

Surgery, Universitätsspital Basel (USB), Basel

CHF 371 190 | 36 months | [KFS-6184-08-2024](#)

Wenning Anna Silvia | TOPANC Trial: Survival after TOtal versus partial PANCreaticoduodenectomy for adenocarcinoma of the pancreatic head, distal cholangiocarcinoma and ampullary cancer: a prospective multi-centric randomized controlled trial

Department for Visceral Surgery and Medicine, Inselspital Bern, Bern

CHF 365 960 | 48 months | [KFS-6043-02-2024](#)

Zilli Thomas | STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer - SABR Comparison S

Radiation Oncology, Ente Ospedaliero Cantonale (EOC), Bellinzona

CHF 373 151 | 48 months | [KFS-6158-08-2024](#)

Epidemiological research

Katapodi Maria | CASCADE III: Designing risk-stratified models of survivorship care for HBOC and Lynch syndrome families

Clinical Research, Faculty of Medicine, Universität Basel, Basel

CHF 374 999 | 36 months | [KFS-6088-02-2024](#)

Rothermundt Christian | Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)

Bereich Onkologie / Hämatologie, Kantonsspital St. Gallen (KSSG), St.Gallen

CHF 217 760 | 48 months | [KFS-6034-02-2024](#)

Schaffar Robin | Cancer risk and prognosis among Individuals with Incarceration Experience: A Comprehensive Study in Geneva, Switzerland

Registre Genevois des Tumeurs, Université de Genève (UNIGE), Genève

CHF 157 338 | 24 months | [KFS-6201-08-2024](#)

Schindera Christina | Prospective multicentre cohort study of cardiac dysfunction in childhood cancer survivors: extension of the CardioOnco Study

University Children's Hospital Basel, Universität Basel, Basel

CHF 374 409 | 36 months | [KFS-6096-02-2024](#)

Spycher Ben D. | Residential exposure to agricultural pesticides and the risk of childhood cancer

Institute of Social and Preventive Medicine, Universität Bern (UniBE), Bern

CHF 351 418 | 36 months | [KFS-6225-08-2024](#)

Health services research

Cathomas Richard | Oncological and functional follow-up after cystectomy and trimodal therapy (INFORMATORY)

Onkologie, Kantonsspital Graubünden (KSGR), Chur

CHF 313 777 | 48 months | [KFS-6065-02-2024](#)

Cobos Munoz Daniel | Enhancing palliative care in Lao PDR: addressing the unmet needs
Epidemiology and Public Health, Schweizerisches Tropen- und Public Health-Institut (Swiss TPH), Allschwil

CHF 276 606 | 36 months | [KFS-6082-02-2024](#)

Maessen Maud | The impact of care goals on costs of inpatient palliative care patients with cancer. Have we been comparing apples and oranges?

University centre of palliative care, Inselspital Bern, Bern

CHF 105 680 | 18 months | [KFS-6062-02-2024](#)

Schwenkglens Matthias | Pre-planned health economic analysis of SAKK 96/12: prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks – a non-inferiority phase III trial

Department of Public Health, Universität Basel, Basel

CHF 88 497 | 30 months | [KFS-6193-08-2024](#)

Tolotti Angela | Advanced Practice Nursing in an oncology palliative care setting and its effects on patient autonomy, engagement and interprofessional collaboration: an implementation mixed-method pre-post study

Nursing research and development unit, Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona

CHF 193 929 | 36 months | [KFS-6023-02-2024](#)

Psychosocial research

Sommer Grit | Exploring trends of health-related quality of life after childhood cancer and its drivers/determinants: A longitudinal study

Institute of Social and Preventive Medicine, Universität Bern (UniBE), Bern

CHF 366 775 | 36 months | [KFS-6105-02-2024](#)

Wünsch Alexander | Empowering medical literacy in patients by pathology, oncology, onconursing and oncop psychology with explanation and rationalisation (EMPPO3WER): feasibility study with mixed methods

Universitätsklinik für Medizinische Onkologie, Inselspital Bern, Bern

CHF 286 408 | 36 months | [KFS-6151-08-2024](#)

Fellowships

Guedj Danaé | Exploring and exploiting HPV-specific CD4 T cells for head and neck squamous cell cancer immunotherapy

Département de pathologie et d'immunologie, Université de Genève (UNIGE), Genève 4

CHF 138 712 | 24 months | [MD-PhD-6133-02-2024](#)

Peres Tobias | Real world data of Nivolumab/Relatlimab in patients with melanoma brain metastasis

Medical Oncology / Hematology, Kantonsspital St. Gallen (KSSG), St. Gallen

CHF 62 600 | 12 months | [KFS-6101-02-2024 BIL](#)

Thavayogarajah Tharshika | Identifying the role of WRN in clonal haematopoiesis
Department of Hematology and Oncology, Universitätsspital Zürich (USZ), Zürich
CHF 126 000 | 24 months | [KFS-6067-02-2024 BIL](#)

Trepl Julia | Deciphering lung cancer metastasis through clonal and microenvironmental analysis
Medizinische Onkologie und Hämatologie, Universitätsspital Zürich (USZ), Zürich
CHF 125 600 | 24 months | [KFS-6220-08-2024 BIL](#)